科普蒂辛通过调节肠道微生物群和抑制TXNIP/NLRP3炎症酶来缓解大肠炎
1Department of Pharmacology, Zunyi Medical University, Zhuhai Campus, Zhuhai 519041, PR China; Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563000, PR China; Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563000, PR China.
科普提辛 (COP) 通过减少炎症和恢复肠道细菌平衡,有效地治疗小鼠的性结肠炎 (UC). 这项研究揭示了COP的潜力,作为UC患者的新疗法.
科学领域:
- 药理学和胃肠病学 药理学和胃肠病学
- 炎症和免疫反应
- 微生物组研究 微生物组研究
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠道疾病.
- 来自Coptis chinensis的Coptisine (COP) 具有抗炎和抗氧化特性.
- 对于大肠炎的COP的精确治疗机制仍然不完全理解.
研究的目的:
- 在硫酸 (DSS) 诱导的性结肠炎 (UC) 的小鼠模型中研究科普蒂辛 (COP) 的治疗机制.
主要方法:
- 在DSS诱导的大肠炎小鼠中,通过口腔输液给药COP和硫沙拉 (SASP).
- 评估氧化应激,炎症性细胞因子,肠道透性,TXNIP/NLRP3炎症途径蛋白表达和肠道微生物组结构.
主要成果:
- COP显著改善了DSS诱导的UC症状,包括体重减轻,疾病活动和结肠损伤.
- COP降低了促炎因素,氧化应激 (MDA,ROS) 和增强了抗氧化活性 (SOD).
- 通过促进有益细菌和抑制致病性细菌,COP调节了TXNIP/NLRP3炎症体通路,并逆转了肠道失生症.
结论:
- 通过抑制TXNIP/NLRP3炎症酶通路和调节肠道微生物群,COP具有抗UC作用.
- 这些发现强调了COP作为性结肠炎的有希望的治疗候选者.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...


